Clinical Trial

Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis

Study acronym: GCA-Biom
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2024 (before its estimated February 18, 2026 completion). Its status may not reflect the trial's current state.
Summary
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients. At diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from GCA patients and healthy controls. Thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-22.
Trial Details
NCT Number NCT06279065
Lead Sponsor University of Bonn
Conditions Giant Cell Arteritis
Enrollment 50 participants
Start Date 2024-02-29
Primary Completion 2026-02-18 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2024-05-09